Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7124867 | 0.99 | HPGDS (0.50) | HPGDSSMYD3KDM4EKDM2BDRD4 | |
| SCHEMBL6100330 | 0.86 | SSTR3 (0.47) | DRD4 | |
| SCHEMBL7119235 | 0.85 | CYP2A6 (0.43) | DRD4NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7126791 | 0.85 | SSTR3 (0.46) | DRD4 | |
| SCHEMBL6098344 | 0.84 | CHRNB4 (0.39) | SMYD3DRD4NPC1RAB9A | |
| SCHEMBL7127599 | 0.84 | NAAA (0.49) | NPC1RAB9AGRM5 | |
| SCHEMBL7121745 | 0.84 | CHRNB2 (0.40) | SMYD3DRD4PLAU | |
| SCHEMBL7124881 | 0.83 | SLC6A2 (0.44) | SMYD3ALDH1A1SMN1; SMN2 | |
| SCHEMBL7124945 | 0.83 | CHRNA7 (0.37) | SMYD3DRD4 | |
| SCHEMBL6100300 | 0.83 | ABL1 (0.43) | HPGDSHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | HPGDS 1949/4885SMYD3 4155/4885KDM4E 392/4885 |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | HPGDS 1600/4885SMYD3 2213/4885KDM4E 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.